期刊文献+

辛伐他汀预处理对大鼠心肌缺血再灌注的影响 被引量:3

Influence of pretreatment with simvastatin on the reperfusion in rats with myocardial ischemia
原文传递
导出
摘要 目的:观察辛伐他汀预处理对大鼠急性心肌缺血的影响,探讨其对心肌的保护机制。方法:40只雄性SD大鼠随机分为3组,假手术组(12只),缺血再灌注组(14只)用等量生理盐水灌胃,辛伐他汀预处理组(14只)用辛伐他汀20 mg/(kg.d),溶于生理盐水中灌胃,每组再平分为2组,分别再灌注30,90 min。所有动物均灌胃14 d,1次/d,第15天建立大鼠心肌缺血再灌注模型,观察大鼠心肌缺血再灌注后心肌组织中髓过氧化物酶、肿瘤坏死因子-α、白细胞介素-4的动态变化。结果:预处理组心肌组织髓过氧化物酶、肿瘤坏死因子-α、白细胞介素-4水平在再灌注30,90 min各时段均低于缺血再灌注组(P<0.05)。结论:辛伐他汀通过改善内皮功能和抗炎作用对缺血再灌注心肌损伤起保护作用。 Objective To explore the protective effects of pretreatment of simvastatin on acute myocardial ischemia in rats. Methods Forty male SD rats were randomly divided into three groups: sham group(n: 12), ischemia-reperfusion group(n= 14), and simvastatin group(n=14). Rats received simvastatin and saline gastric gavage once a day, totally for 14 days. And on the 15th day, the ischemic-reperfused models were established. Each group was divided into 2 subgroups 30-rain and 90-rain reperfusion groups. The levels of myocardial myeloperoxidase, tumor necrosis factor α and interlukin 4 were measured. Results The levels of myocardial myocardial myeloperoxidase, tumor necrosis faetor-α and interlukin 4 were lower after 30 and 90 minutes reperfusion in simvastatin group than those in ischemic-reperfused group (P〈0.05). Conclusion Pretreatment with simvastatin has a protective effect on ischemie-reperfused myocardium by improving endothelial function and antiinflammatory effect.
出处 《中华实用诊断与治疗杂志》 2010年第9期867-869,共3页 Journal of Chinese Practical Diagnosis and Therapy
关键词 心肌缺血 辛伐他汀 预处理 心肌再灌注损伤 Myocardial isehemia simvastatin pretreatment myocardial reperfusion injury
  • 相关文献

参考文献9

  • 1Ito MK, Talbert RL, TsimikasS. Statinassociated pleiotropy: possible beneficial effects beyond cholesterol reduction [J]. Pharmacotherapy,2006,26(6) :85- 97.
  • 2Scalia R. Statins and the response to myocardial injury[J]. Cardiovas Drugs, 2005,5(3) :163- 168.
  • 3陈书艳,桑震池,李月华,王长谦,李毅刚.氯吡格雷在冠心病患者中对阿托伐他汀降脂的影响[J].实用诊断与治疗杂志,2007,21(5):336-338. 被引量:10
  • 4Weinberg E O, Scherrer-Crosbie M, Picard M H, et al. Rosuvastatin reduces experimental left ventricular infarct size after isehemia reperfusion injury but not total coronary occlusion [J]. AmJ PhysiolHeart CircPhysiol,2005,288(4):1802-1809.
  • 5Di Napoli P, Taccadi A A, Grilli A, et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia reperfusion injury in rat hcarts[J].Cardiovasc Res,2005,66(3):462- 471.
  • 6Byrne I G, Karavas A N, Ehalabi A, et al. Myocardial neutrophil sequestration during reperfusion of the transplanted rabbit heart[J].J Heart Lung Transplant, 2000, 19 (8):786- 793.
  • 7Elizabeth N, Morgan M D, Edward M, et al. An essential role of NF-kB in the cardioadaptive response to ischemia[J], Ann Thorac Surg, 1999,68(2) :377- 382.
  • 8Ortego M, Bustos C, Herndndez Presa M A, et al. Atorvastatin reduces NF kappaB activation vascular Smooth muscle cells and chemokine expression in and mononuclear cells [ J ]. Atherosclerosis,1999,147(2), 253- 261.
  • 9Kato A, Yoshidome H, Edwards M J, et al. Reduced hepatic ischemia/reperfusion injury by IL- 4: potential anti inflammatory role of STAT6[J]. Inflamm Res,2000,49(6):275 -279.

二级参考文献17

  • 1周跟东,施有为,丁晓梅.急性冠状动脉综合征患者血清C-反应蛋白和肿瘤坏死因子-α水平的变化及辛伐他汀对其影响[J].实用诊断与治疗杂志,2006,20(11):809-812. 被引量:3
  • 2Muller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clop idogrel[J]. Circulation,2003,108(18):2195-2197.
  • 3Wienbergen H, Girt A K, Schiele R, et al. Comparison of clinical benefits of clop idogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies[J]. Am J Cardiol, 2003,92(3):285-288.
  • 4Mukherjee D, Kline Rogers E, Fang J, et al. Lack of clopidogrel CYP3A4 statin interaction in patientswith acute coronary syndrome[J]. Heart, 2005,91 ( 1 ) : 23-26.
  • 5The clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J]. N Engl J Med ,2001,345(7) :494-502.
  • 6Lau W C, Waskell L A, Watkins P B, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation.A new drug-drug interaction[J]. Circulation, 2003, 107(1):32-37.
  • 7Pravastatin or Atorvastatin Evaluation and Infection TherapyThrombolysis in Myocardial Infarction (PROVE-IT-TIMI 22)Investigators. C-reactive protein levels and outcomes after statin therapy[J]. N Engl J Med, 2005,352(1):20-28.
  • 8Nissen S E, Tuzcu E M, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial[J]. JAMA,2004,291 (9): 1071-1080.
  • 9Pravastatin or Atorvastatin Evaluation and Infection TherapyThrombolysis in Myocardial Infarction 22 Investigators.Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J]. N Engl J Med,2004,350(15):1495-1504.
  • 10Steven E, Nissen, M D. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an earlybenefit from the reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) trial [J]. Am J Cardiol, 2005, 96[Suppl ] : 61 F- 68F.

共引文献9

同被引文献52

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部